Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

268

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

February 1, 2025

Conditions

H. Pylori Infection

Interventions

DRUG

Keverprazan

Potassium-competitive acid blocker

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

All Listed Sponsors

lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT06412640 - Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori | Biotech Hunter | Biotech Hunter